Radiopharm Theranostics Limited Statistics
Want to see AU:RAD full AI Analyst Report?
Radiopharm Theranostics Limited (RAD) Stock Statistics & Valuation Metrics
Total Valuation
Radiopharm Theranostics Limited has a market cap or net worth of AUD 18.84M. The enterprise value is AUD 60.84M.
- Market Cap
- AUD 18.84M
- Enterprise Value
- AUD 60.84M
Share Statistics
Radiopharm Theranostics Limited has 4,710,883,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,710,883,000
- Owned by Insiders
- 4.09%
- Owned by Institutions
- ―
Financial Efficiency
Radiopharm Theranostics Limited’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -165.54%.
- Return on Equity (ROE)
- -2.23
- Return on Assets (ROA)
- -0.92
- Return on Invested Capital (ROIC)
- -165.54%
- Return on Capital Employed (ROCE)
- -1.66
- Revenue Per Employee
- 197.71K
- Profits Per Employee
- -3.94M
- Employee Count
- 14
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited is -0.26. Radiopharm Theranostics Limited’s PEG ratio is -0.00.
- PE Ratio
- -0.26
- PS Ratio
- 3.42
- PB Ratio
- 0.57
- Price to FCF
- -0.42
- Price to Operating Cash Flow
- -0.27
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Radiopharm Theranostics Limited had revenue of 2.77M and earned -55.15M in profits. Earnings per share was -0.02.
- Revenue
- 2.77M
- Gross Profit
- -2.15M
- Operating Income
- -68.33M
- Pretax Income
- -56.90M
- Net Income
- -55.15M
- EBITDA
- -68.32M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -52.78M and capital expenditures 30.11M, giving a free cash flow of -22.67M billion.
- Operating Cash Flow
- -52.78M
- Free Cash Flow
- -22.67M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Radiopharm Theranostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -239.67%
- Earnings Yield
- -391.36%
Stock Price Statistics
- Beta
- 0.74
- 52-Week Price Change
- -64.29%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- 33.27
- Average Volume (3m)
- 9.49M
Important Dates
Radiopharm Theranostics Limited upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Radiopharm Theranostics Limited as a current ratio of 1.16, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.16
- Quick Ratio
- 1.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.06
- Interest Coverage Ratio
- -607.93
Taxes
In the past 12 months, Radiopharm Theranostics Limited has paid -54.44K in taxes.
- Income Tax
- -54.44K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Radiopharm Theranostics Limited EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.23.
- EV to Sales
- 1.92
- EV to EBITDA
- -0.08
- EV to Free Cash Flow
- -0.23
- EV to Operating Cash Flow
- -0.10
Balance Sheet
Radiopharm Theranostics Limited has AUD 4.14M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 4.14M billion.
- Cash & Marketable Securities
- AUD 4.14M
- Total Debt
- AUD 0.00
- Net Cash
- AUD 4.14M
- Net Cash Per Share
- AUD 0.00
- Tangible Book Value Per Share
- AUD 0.00
Margins
Gross margin is -39.41%, with operating margin of -2545.78%, and net profit margin of -1992.46%.
- Gross Margin
- -39.41%
- Operating Margin
- -2545.78%
- Pretax Margin
- -2219.93%
- Net Profit Margin
- -1992.46%
- EBITDA Margin
- -2496.85%
- EBIT Margin
- -2545.78%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -23.82%
- EPS Growth Forecast
- 12.36%
Scores
- Smart Score
- 8
- AI Score
- 42
